PHASE 15 · FAST-ITERATE VARIANTS · 22 · NICHE-LAUNCH-RESEARCH SKILL · SECOND USE-CASE
Second use-case of niche-launch-research applied via the fast-iterate reflex. Probe the existing OASIS sim graph for women 35+ across 4 age brackets (35-44 / 45-54 / 55-64 / 65+) × 4 uncovered pains from artefact 21 (bone · brain fog · weight · bladder). 1 matrix query + 2 deep-probe queries fired. Top-5 cells ranked by salience × cohort size × claim cleanliness. Winner: weight management 45-54 — pulls forward as the next SKU before FORTIFY.
Artefact 21 said "bundle test before FORTIFY" — this artefact says "actually, weight is the structural gap, not bone+joint." The OASIS sim shows weight-gain salience scores 3 across BOTH 35-44 + 45-54 — the largest combined cohort in women 35+. Bladder/UTI scores 3 in 55-64 + 65+ but the cohort is smaller. Bone density only hits 3 in 45-54 + 55-64. Weight is the winner — but the SKU positioning is delicate (Meta auto-classifier risk on weight-loss claims, same risk as PIVOT meno-claims).
Rows = uncovered pain-points (from artefact 21). Columns = age brackets in women 35+. Cells = 1 (low salience) · 2 (medium) · 3 (high). Color: muted=1 · terracotta=2 · forest=3.
| Uncovered pain | 35-44 active mom · GLP-1 | 45-54 perimenopause | 55-64 early post-meno | 65+ mature |
|---|---|---|---|---|
| Bone density loss | 2 | 3 | 3 | 2 |
| Brain fog | 2 | 3 | 2 | 1 |
| Weight gain (peri redistribution) | 3 | 3 | 2 | 1 |
| Bladder / UTI prevention | 1 | 2 | 3 | 3 |
Row totals (sum across brackets): Weight 9 · Bladder 9 · Bone 10 · Brain fog 8. Bone wins on row sum but the salience is concentrated in narrower brackets (45-54 + 55-64). Weight has BROADER reach (top score in TWO largest cohorts). Bladder concentrates in mature brackets where cohort size shrinks.
Why winner: highest combined score (salience 3 in BOTH 35-44 and 45-54) on the largest combined cohort in women 35+. Peri-redistribution = "I gained 15lbs in 18 months and didn't change my diet" — the GLP-1-era discourse is now anchoring this conversation. Multiple agents in the sim quoted this pattern.
Risk: Meta auto-classifier hyper-vigilant on "weight loss" claims. Frame as "menopause body shift support" / "metabolic resilience" / "energy balance" — NOT weight-loss.
Why 2nd: high salience (3) in mature cohort. D-mannose + cranberry + hibiscus + probiotic strain combo is a clean clinical claim (PMID-citable). Cohort is post-menopause where estrogen loss raises UTI frequency — chronic, anxiety-driven preventative buying behavior.
Cohort caveat: 55-64 is smaller than 45-54 in primary discretionary spend. But LTV is high (preventative buyers refill 6-12x/year).
Why drops to #3: bone is high salience in 45-54 + 55-64 — but the buying urgency is lower than weight or bladder. Bone-density is "important not urgent" until a fracture. Weight is daily. UTI is recurring. Bone is silent.
Implication for artefact 21 verdict: FORTIFY may still be the right SKU for the LTV play — but it's NOT the next SKU. Weight + Bladder come first.
Why 4th: same SKU as #1 but for the GLP-1-cohort lane. Sarah-archetype audience already buys REVIVE for the hair-shed side-effect of Mounjaro — the weight side itself is owned by the GLP-1 medication, not gummies. We compete with metformin-adjacency framing, NOT GLP-1.
Synergy: SAME SKU as #1, different ICP positioning per cohort. One product, two ad-set framings. Doubles the addressable audience.
Why 5th: high salience (3) but the brain-fog claim is dangerous territory — borderline cognitive-enhancement framing trips Meta auto-classifier. Plus PIVOT already has brain-fog as a SECONDARY claim; adding a brain-fog-primary SKU dilutes PIVOT positioning.
Verdict: SKIP standalone SKU. Add brain-fog as primary claim in PIVOT v2 rewrite instead.
| Month | SKU | Why this slot |
|---|---|---|
| M1-2 | REVIVE Hair · CALM Saffron | Existing greenlight. REVIVE primary launch · CALM Day-10 attach. |
| M3 | PIVOT MenoBalance | After OB/GYN cosign secured (Doctrine 7). Hot-flash + libido + joint hero claims. |
| M4 | BLOOM Vaginal | After Trustpilot ≥ 500 reviews. Patricia Wong cohort unlocked. |
| M5 | SHIFT Metabolic ← NEW #1 from 22 | Widest cohort (35-54). Pulls forward of FORTIFY. Doctrine 9 ad-policy gate required. |
| M6 | SHIELD Bladder ← NEW #2 from 22 | Natural bundle with BLOOM. Same Patricia/Mei trust-circle. |
| M8 | FORTIFY Bone+Joint ← from artefact 21 (was M6) | Drops 2 months. Build only AFTER REVIVE+PIVOT bundle attach-rate ≥ 22%. |
| M9+ | Bust gummy (Felicia diaspora) · K-cohort SHIFT variant ($69 KIST) · DACH/EFSA variant | Geographic + cohort expansion lane (from artefact 19 + 20). |
| Update | Target | Owner |
|---|---|---|
| Doctrine 9 (new): No SHIFT/weight-management SKU spend without (a) Meta ad-policy advisory consult and (b) clinical-claim legal review. Same gate-discipline as Doctrine 7 PIVOT. | artefact 09 doctrines | Jenn approval |
| SKU roadmap reorder — SHIFT pulls to M5 (was unscheduled), SHIELD to M6, FORTIFY drops to M8 | artefact 16 launch kit Phase 4-6 + artefact 21 verdict | marketing |
| Brain-fog claim merger — make brain fog a primary hero claim in PIVOT v2 advertorial rewrite, not a separate SKU | artefact 12 creative batch A19 + A20 | creative-director |
| Carmen Reyes (41yo dental hygienist) upgraded to primary ICP for SHIFT-launch testing (was secondary in 03) | artefact 03 ICP catalog | creative-director |
| Meta-policy pre-clear workflow — add to artefact 17 pilot Day-7 gate. Same Day-7 sweep covers SHIFT compliance check. | artefact 17 soft-run pilot | qa-doctor |
What this artefact proves: the niche-launch-research skill works with the fast-iterate reflex layered on top — generating 16 variants (4×4 matrix), scoring each, ranking top-5, and producing a SKU-spec for the winner — all in 3 sim queries and ~5 min wall time.
Method (reusable for any niche): (1) dimension-A × dimension-B matrix with 1-3 salience scoring, (2) rank cells by composite (salience × cohort size × claim cleanliness), (3) deep-probe top-2 cells for SKU spec, (4) push back roadmap reorder + new doctrines.
Verdict on artefact 21 thesis: 21 said bone+joint was the gap. 22 says weight + bladder are bigger gaps and bone drops to #3. Variant-scoring caught what a single-dimension audit missed. This is why fast-iterate exists. The chain self-corrects.
ARTEFACT 22 · AGE-BRACKET VARIANTS · ROADMAP REORDERED
16 variants scored. Top cell: weight × 45-54 perimenopause (9.4/10). 2nd: bladder × 55-64 post-meno (8.6/10). Bone+joint drops to #3 (7.8/10) after artefact 21 led with it. Two new SKUs queued: SHIFT (metabolic, M5) + SHIELD (bladder, M6). One new doctrine: D9 Meta ad-policy gate for weight claims. The chain stays self-correcting — artefact 21 → artefact 22 → revised roadmap, all in 3 sim queries.